计算溶液所需的质量、体积或浓度。
为什么选择此级别
提供 ≥98% 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
2-8°C储存,避光,干燥。低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L 1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates ( EC 50 =0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV).
In Vitro
AVG-233 (1-100 μM) blocks 3´RNA extension elongation but does not interfere with 3´RNA extension by up to three nucleotides after de novo initiation from the promoter or back-priming. AVG-233 (20 μM) reduces virus yield of RSV A2-L19F (EC 50 =0.31 μM), RSV strain 2-20 (EC 50 =0.14 μM) and RSV clinical isolate 718 (EC 50 =0.2 μM). AVG-233 (1.25-40 μM; 0-300 s) suppresses RNA synthesis by the L1-1749 fragment in a dose-dependent manner with an IC 50 value of 13.7 μM. AVG-233 bounds L and the L 1-1749 fragment with similar affinities (dissociation constants (KD’s) are 38.3 μM and 53.1 μM, respectively). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
AVG-233 (50-100 mg/kg; i.g.; once) decreases lung viral load in the RSV mouse model. AVG-233 (2-20 mg/kg; i.v. and p.o.; once; male CD-1 mice) has good orally bioavailable and the maximum plasma concentration about 2 μM . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Balb/cJ mice with recRSV-mKate xenograftDosage: 50 and 100 mg/kg Administration: Oral gavage; once Result: Reduced in lung viral load of 0.89 log 10 TCID 50 (median tissue culture infectious dose)/mL. Animal Model: Male CD-1 mice (27-29 g) Dosage: 2 mg/kg (i.v.) and 20 mg/kg (p.o.) Administration: Intravenous injection and oral administration; once, obtains blood samples at pre-dose and 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h post-dosing Result: 1.19 Route Dose T max C max AUC 0-∞ CL/F T 1/2 Bioavailability mg/kg h nmol/ml h×nmol/ml liters/h/kg h % Oral 20 1 2.17 5.95 6.98 5.28 33.8
Form:Solid
规格
规格或纯度
≥98%
英文名称
AVG-233
生化机理
AVG-233 是一种强效的口服活性 RNA 依赖性 RNA 聚合酶（RdRp）抑制剂。AVG-233 可阻止病毒聚合酶复合物在启动子处启动。AVG-233 的结合位点存在于 L 1-1749 片段中。AVG-233 对以下病毒具有纳摩尔活性
储存条件
2-8°C储存,避光,干燥
运输条件
低温运输
作用类型
抑制剂
纯度
≥98%
名称和识别符
分子类型
小分子
分子量
487.94
技术文档
高级数据
化学和物理性质
溶解性
DMSO : 50 mg/mL (102.47 mM; ultrasonic and warming and heat to 60°C)
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）